Based on this trial, the National Medical Products Administration (NMPA) of China has approved toripalimab in combination with pemetrexed and platinum as the first-line treatment for patients with inoperable, locally advanced, or metastatic NSCLC that is negative for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.